Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Janssen, Takeda to Expand Share of Reminyl through Comarketing
June 27, 2011
- JACDS Draws Up GL for Power Saving This Summer
June 27, 2011
- TS-1 Non-Inferior to Gemcitabine in Pancreatic Cancer: Taiho
June 27, 2011
- Study Group to Discuss System for Relieving Victims of Health Damage Due to Anticancer Drugs
June 27, 2011
- Combined Sales of 24 Drug Makers Show Zero Growth
June 27, 2011
- FDA Approves Ciclesonide in Alternative HFA for Rhinitis: DSP
June 27, 2011
- Sanofi: Lyxumia Plus Insulin Shows Promise in PIII Study
June 27, 2011
- Korosho Council Approves Draft Report on Measures against Rheumatism, Allergy
June 27, 2011
- JPMA Suspends MSD from Membership for Violations of Promotion Code
June 27, 2011
- Novoseven Approved for Glanzmann Thrombasthenia
June 27, 2011
- Zeria's Z-338 Effective for 3 Major Meal-related Symptoms
June 27, 2011
- Doctors Appreciate Companies That Supply Information in Emergencies
June 27, 2011
- HeW CO-OP JAPAN Aims to Jointly Purchase ¥3 Bil. Worth of Drugs in FY2011
June 27, 2011
- Bayer HealthCare Applies for VEGF Trap-Eye in Europe
June 27, 2011
- Radioactive Anticancer Agent Significantly Extends OS in PIII Study: Bayer HealthCare
June 27, 2011
- Mediceo Aims to Attract More Customers in Nagoya Area through New ALC
June 27, 2011
- Sanofi to Apply for Zaltrap for mCRC in Europe, US in 2011
June 27, 2011
- Terumo to Expand into Infusion Products Market in China
June 27, 2011
- MSD, Taiho Announce Marketing Tie-up for CTCL Treatment Vorinostat
June 27, 2011
- More Companies Collaborating in Development of Combination Therapies Using New Drugs
June 27, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…